This company is no longer active
Clarus Therapeutics Holdings Management
Management criteria checks 0/4
Key information
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | 1.4yrs |
| Board average tenure | no data |
CEO
Clarus Therapeutics Holdings has no CEO, or we have no data on them.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Director | 19yrs | US$2.48m | 0.0088% $ 5.0 | |
| Vice President of Commercial Analytics & Operations | no data | no data | no data | |
| Vice President of Marketing | no data | no data | no data | |
| Vice President of Sales | 1.1yrs | no data | no data | |
| Chief Medical Officer | 1.4yrs | no data | no data | |
| Senior Vice President of Manufacturing & Supply | 1.4yrs | no data | no data | |
| Chief Restructuring Officer | no data | no data | no data |
1.4yrs
Average Tenure
Experienced Management: CRXT.Q's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/10 07:52 |
| End of Day Share Price | 2023/02/09 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clarus Therapeutics Holdings, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Jason McCarthy | Maxim Group |
| Nazibur Rahman | Maxim Group |